Enzalutamide versus bicalutamide in castration-resistant prostate cancer: The STRIVE trial

Journal of Clinical Oncology

Volumn 34, Issue 18, 2016, Pages 2098-2106

  Penson, David F ^a   Armstrong, Andrew J ^c   Concepcion, Raoul ^b   Agarwal, Neeraj ^d   Olsson, Carl ^e   Karsh, Lawrence ^f   Dunshee, Curtis ^g   Wang, Fong ^h   Wu, Kenneth ^h   Krivoshik, Andrew ⁱ   Phung, De ^j   Higano, Celestia S ^k  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b Urology Associates   (United States)

^c DUKE CANCER INSTITUTE   (United States)

^d UNIVERSITY OF UTAH   (United States)

^e MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^f Urology Center of Colorado   (United States)

^g Urological Associates of Southern Arizona   (United States)

^h Medivation Inc   (United States)

ⁱ ASTELLAS PHARMA GLOBAL DEVELOPMENT   (United States)

^j Astellas Pharma Global Development   (Netherlands)

^k UNIVERSITY OF WASHINGTON   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BICALUTAMIDE; ENZALUTAMIDE; PROSTATE SPECIFIC ANTIGEN; ANILIDE; ANTIANDROGEN; ANTINEOPLASTIC AGENT; NITRILE; PHENYLTHIOHYDANTOIN; TOLUENESULFONIC ACID DERIVATIVE;

AGED; ANDROGEN DEPRIVATION THERAPY; ANEMIA; ARTICLE; BACKACHE; CANCER GROWTH; CANCER RISK; CASTRATION RESISTANT PROSTATE CANCER; CLINICAL EFFECTIVENESS; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; DECREASED APPETITE; DIARRHEA; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FALLING; FATIGUE; HOT FLUSH; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; RISK REDUCTION; SEIZURE; TREATMENT DURATION; URINARY TRACT INFECTION; ADULT; ANALOGS AND DERIVATIVES; BLOOD; CLINICAL TRIAL; COMPARATIVE STUDY; MIDDLE AGED; MORTALITY; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT;

ADULT; AGED; ANDROGEN ANTAGONISTS; ANILIDES; ANTINEOPLASTIC AGENTS; DOUBLE-BLIND METHOD; HUMANS; MALE; MIDDLE AGED; NITRILES; PHENYLTHIOHYDANTOIN; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; TOSYL COMPOUNDS;

EID: 84962771526     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2015.64.9285     Document Type: Article

References (28)

1. National Comprehensive Cancer Network: Clinical Practice Guidelines for Prostate Cancer, 2015. http://www.nccn.org/professionals/physician-gls/pdf/prostate.pdf
2. Hotte SJ, Saad F: Current management of castrate-resistant prostate cancer. Curr Oncol 17:S72-S79, 2010 (Suppl 2)
3. Scher HI, Fizazi K, Saad F, et al: Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 367:1187-1197, 2012
4. Beer TM, Armstrong AJ, Rathkopf DE, et al: Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med 371:424-433, 2014
5. de Bono JS, Logothetis CJ, Molina A, et al: Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 364:1995-2005, 2011
6. Ryan CJ, Smith MR, de Bono JS, et al: Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med 368:138-148, 2013
7. de Bono JS, Oudard S, Ozguroglu M, et al: Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: A randomised open-label trial. Lancet 376:1147-1154, 2010
8. Kantoff PW, Higano CS, Shore ND, et al: Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 363:411-422, 2010
9. Parker C, Nilsson S, Heinrich D, et al: Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med 369:213-223, 2013
10. Azad AA, Beardsley EK, Hotte SJ, et al: A randomized phase II efficacy and safety study of vandetanib (ZD6474) in combination with bicalutamide versus bicalutamide alone in patients with chemotherapy naïve castration-resistant prostate cancer. Invest New Drugs 32:746-752, 2014
11. Kucuk O, Fisher E, Moinpour CM, et al: Phase II trial of bicalutamide in patients with advanced prostate cancer in whom conventional hormonal therapy failed: A Southwest Oncology Group study (SWOG 9235). Urology 58:53-58, 2001
12. Joyce R, Fenton MA, Rode P, et al: High dose bicalutamide for androgen independent prostate cancer: Effect of prior hormonal therapy. J Urol 159:149-153, 1998
13. Scher HI, Liebertz C, Kelly WK, et al: Bicalutamide for advanced prostate cancer: The natural versus treated history of disease. J Clin Oncol 15:2928-2938, 1997
14. Tombal B: Non-metastatic CRPC and asymptomatic metastatic CRPC: Which treatment for which patient? Ann Oncol 23: x251-x258, 2012 (Suppl 10)
15. Culig Z, Hoffmann J, Erdel M, et al: Switch from antagonist to agonist of the androgen receptor bicalutamide is associated with prostate tumour progression in a new model system. Br J Cancer 81:242-251, 1999
16. Chen Y, Sawyers CL, Scher HI: Targeting the androgen receptor pathway in prostate cancer. Curr Opin Pharmacol 8:440-448, 2008
17. Scher HI, Kelly WK: Flutamide withdrawal syndrome: Its impact on clinical trials in hormone-refractory prostate cancer. J Clin Oncol 11:1566-1572, 1993
18. Small EJ, Srinivas S: The antiandrogen withdrawal syndrome: Experience in a large cohort of unselected patients with advanced prostate cancer. Cancer 76:1428-1434, 1995
19. Figg WD, Sartor O, Cooper MR, et al: Prostate specific antigen decline following the discontinuation of flutamide in patients with stage D2 prostate cancer. Am J Med 98:412-414, 1995
20. Jung ME, Ouk S, Yoo D, et al: Structure-activity relationship for thiohydantoin androgen receptor antagonists for castration-resistant prostate cancer (CRPC). J Med Chem 53:2779-2796, 2010
21. Tran C, Ouk S, Clegg NJ, et al: Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science 324:787-790, 2009
22. Guerrero J, Alfaro IE, Gómez F, et al: Enzalutamide, an androgen receptor signaling inhibitor, induces tumor regression in a mouse model of castration-resistant prostate cancer. Prostate 73:1291-1305, 2013
23. Scher HI, Halabi S, Tannock I, et al: Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: Recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol 26:1148-1159, 2008
24. Eisenhauer EA, Therasse P, Bogaerts J, et al: New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer 45:228-247, 2009
25. McLeod DG, Iversen P, See WA, et al: Bicalutamide 150 mg plus standard care vs standard care alone for early prostate cancer. BJU Int 97:247-254, 2006
26. Schellhammer PF, Sharifi R, Block NL, et al: A controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy, in patients with advanced prostate carcinoma: Analysis of time to progression. Cancer 78:2164-2169, 1996
27. Schellhammer PF, Sharifi R, Block NL, et al: Clinical benefits of bicalutamide compared with flutamide in combined androgen blockade for patients with advanced prostatic carcinoma: Final report of a double-blind, randomized, multicenter trial. Urology 50:330-336, 1997
28. Ning YM, Brave M, Maher VE, et al: US Food and Drug Administration approval summary: Enzalutamide for the treatment of patients with chemotherapy-naïve metastatic castration-resistant prostate cancer. Oncologist 20:960-966, 2015